Comparative study of MP-azeflu in saline nasal irrigation for treatment of allergic rhinitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20210603003

Enrollment

Registered

2021-06-03

Start date

2021-06-15

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate to severe allergic rhinitis MP-azeflu nasal irrigation for control symptom

Interventions

MP-azeflu in saline irrigation,saline irrigation

Experimental Drug,Placebo Comparator Drug

treatment arm,placebo arm

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1 moderate to severe allergic rhinitis 2 allergic confirmation test

Exclusion criteria

Exclusion criteria: 1 recurrent epistaxis 2 previous nasal surgery 3 pregnancy 4 immunocompromised host

Design outcomes

Primary

Measure	Time frame
nasal symptom At 4 week and 8 week after start treatment Total nasal symptoms score	—

Secondary

Measure	Time frame
side effect of medication At 4 week and 8 week after start treatment questionnaire	—

Countries

Thailand

Contacts

Public ContactPisit Wanichakoontrakul

Srinakharinwirot university

pisitw@g.swu.ac.th037395085

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026